Search

Your search keyword '"S, Pisconti"' showing total 3 results
Start Over Author "S, Pisconti" Journal british journal of cancer
3 results on '"S, Pisconti"'

1. Erratum: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

Author

R V, Iaffaioli, R, Formato, A, Tortoriello, S, Del Prete, M, Caraglia, G, Pappagallo, A, Pisano, V, Gebbia, F, Fanelli, G, Ianniello, S, Cigolari, C, Pizza, O, Marano, G, Pezzella, T, Pedicini, A, Febbraro, P, Incoronato, L, Manzione, E, Ferrari, N, Marzano, S, Quattrin, S, Pisconti, G, Nasti, G, Giotta, G, Colucci, IAFFAIOLI RV, FORMATO R, TORTORIELLO A, DEL PRETE S, CARAGLIA M, PAPPAGALLO, PISANO A, GEBBIA V, FANELLI F, IANNIELLO G, CIGOLARI S, PIZZA C, MARANO O, PEZZELLA G, PEDICINI T, FEBBRARO A, INCORONATO P, MANZIONE L, FERRARI E, MARZANO, QUATTRIN S, PISCONTI S, NASTI G, GIOTTA G, and COLUCCI G

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, Neoplasms, Hormone-Dependent, Antineoplastic Agents, Hormonal, medicine.medical_treatment, Administration, Oral, Phases of clinical research, Anastrozole, Breast Neoplasms, Metastasis, chemistry.chemical_compound, breast cancer, Breast cancer, Exemestane, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Clinical Studies, Humans, Medicine, Aged, Gynecology, business.industry, sequential hormonal therapy, Cancer, Middle Aged, Triazoles, medicine.disease, Metastatic breast cancer, Androstadienes, chemistry, Chemotherapy, Adjuvant, Hormonal therapy, Female, Hormone therapy, Corrigendum, business, medicine.drug
Abstract

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression, followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit, defined as the sum of complete responses (CR), partial responses (PR) and > 24 weeks stable disease (SD). In all, 100 patients were enrolled in the study. Anastrozole produced eight CR and 19 PR for an overall response rate of 27% (95% CI: 18.6-36.8%). An additional 46 patients had long-term (> 24 weeks) SD for an overall clinical benefit of 73% (95% CI: 63.2-81.4). Median time to progression (TTP) was 11 months (95% CI: 10-12). A total of 50 patients were evaluated for the second-line treatment: exemestane produced one CR and three PR; 25 patients had SD which lasted ≥ 6 months in 18 patients. Median TTP was 5 months. Toxicity of treatment was low. Our study confirms that treatment with sequential hormonal agents can extend the period of time during which endocrine therapy can be used, thereby deferring the decision to use chemotherapy. © 2005 Cancer Research UK.

Published
2005
Full Text
View/download PDF

2. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.

Author

Adamo V, Lorusso V, Rossello R, Adamo B, Ferraro G, Lorusso D, Condemi G, Priolo D, Di Lullo L, Paglia A, Pisconti S, Scambia G, and Ferrandina G

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Doxorubicin administration & dosage, Doxorubicin adverse effects, Doxorubicin analogs & derivatives, Female, Humans, Middle Aged, Neoplasm Metastasis, Polyethylene Glycols administration & dosage, Polyethylene Glycols adverse effects, Recurrence, Treatment Outcome, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
Abstract

This multicentre phase II study was aimed at investigating the activity and safety of pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) as front-line therapy in a large series of chemotherapy-naïve recurrent/metastatic breast cancer patients. From June 2003 to December 2006, a total of 71 recurrent/metastatic breast cancer patients were enrolled. Median age was 63 years (range=37-79), and 31 patients (43.7%) were > or =65 years old. Patients received PLD, 25 mg m(-2), day 1, followed by GEM, 800 mg m(-2), days 1 and 8, q21. Response was evaluable in 64 cases. Eight complete (12.5%) and 17 partial responses (26.6%) were registered, with an overall response rate of 39.1%. Thirty patients (46.9%) experienced stable disease, with an overall clinical benefit of 85.9%. Median time to progression (TTP) was 11 months, whereas median overall survival (OS) was not reached. The rate of 1- and 2-year OS was 79 and 61%, respectively. A total of 443 courses were evaluable for toxicity: grade 3 and 4 neutropaenia affected 14 patients (20.3%) and 3 patients (4.3%), respectively. Grade 3 and 4 palmar-plantar erythrodysesthesia syndrome was documented in five cases (7.2%) and one case (1.4%), whereas grade 3 and 4 mucositis occurred in six cases (8.7%) and two cases (2.9%), respectively. Grade 2 cardiac toxicity was observed in only one case. Interestingly enough, there was no difference in the percentage and severity of either haematological or non-haematological toxicity according to the age of the patients (<65 vs > or =65 years). We confirmed in a large, very homogenous study sample of chemotherapy-naïve recurrent/metastatic breast cancer patients the efficacy and safety of PLD/GEM combination, providing response rates, median TTP and OS values comparable with those achieved with more toxic combinations.

Published
2008
Full Text
View/download PDF

3. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.

Author

Iaffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G, Cigolari S, Pizza C, Marano O, Pezzella G, Pedicini T, Febbraro A, Incoronato P, Manzione L, Ferrari E, Marzano N, Quattrin S, Pisconti S, Nasti G, Giotta G, and Colucci G

Subjects
Administration, Oral, Adult, Aged, Anastrozole, Androstadienes administration & dosage, Antineoplastic Agents, Hormonal administration & dosage, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoplasms, Hormone-Dependent drug therapy, Nitriles administration & dosage, Triazoles administration & dosage, Androstadienes therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Nitriles therapeutic use, Triazoles therapeutic use
Abstract

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression, followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit, defined as the sum of complete responses (CR), partial responses (PR) and > 24 weeks stable disease (SD). In all, 100 patients were enrolled in the study. Anastrozole produced eight CR and 19 PR for an overall response rate of 27% (95% CI: 18.6-36.8%). An additional 46 patients had long-term (> 24 weeks) SD for an overall clinical benefit of 73% (95% CI: 63.2-81.4). Median time to progression (TTP) was 11 months (95% CI: 10-12). A total of 50 patients were evaluated for the second-line treatment: exemestane produced one CR and three PR; 25 patients had SD which lasted > or = 6 months in 18 patients. Median TTP was 5 months. Toxicity of treatment was low. Our study confirms that treatment with sequential hormonal agents can extend the period of time during which endocrine therapy can be used, thereby deferring the decision to use chemotherapy.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results